Neil Kumar

Meet Neil Kumar

Prior to founding BridgeBio in 2015, Kumar served as a principal at Third Rock Ventures, the interim vice president of business development at MyoKardia, and an associate principal at McKinsey & Company. “What are the most exciting technologies that will drive the future of pharma? There are so many! To start, technologies that help us better interrogate genetics and link DNA sequence to RNA transcription and protein translation, through more sensitive transcriptomics (single cell and bulk) and quantitative mass spectrometry proteomics. Second, we have more and better quality datasets of human mutations which help us identify new, causal pathogenic variants in different populations. Third, we have made rapid progress on technologies like cryo-EM and CRISPR screens to understand the effect of mutations on protein structure, cellular function and systems dysregulation. The confluence of these technologies promises better medicines to patients faster in the future.”